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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
The aim of this review is to assess the efficacy and safety of interventions for fatigue in IBD.
B A C K G R O U N D
Description of the condition
Inflammatory bowel disease (IBD) represents a group of chronic,
progressive, complex inflammatory disorders of the digestive tract,
and approximately five million people have a diagnosis of IBD
worldwide (Wilson 2012). Crohn’s disease (CD) and ulcerative
colitis (UC) are the twomost common forms of IBD.Both diseases
are characterised by periods of relapse and remission, and they
have overlapping and distinct pathological and clinical features
(Bernstein 2010). Individuals with CD or UC experience a wide
range of symptoms including diarrhoea, abdominal pain, fatigue,
weight loss and rectal bleeding (Cronin 2005).
Fatigue has been identified as one of the most burdensome symp-
toms experienced by individuals with IBD (Farrell 2013). This
symptom is particularly problematic during active disease with
prevalence rates reported as high as 86% (Minderhoud 2007).
A number of studies report that between 40% to 83% of pa-
tients continue to experience high rates of fatigue during remis-
sion (Minderhoud 2003; Romberg-Camps 2010; Van Langenberg
2010; Wilson 2012; Vogelaar 2014). These high rates of fatigue
are comparable with rates experienced by oncology patients (Stone
2008). Furthermore, a study by Jelsness-Jørgensen 2011a found
that chronic fatigue, defined as substantial fatigue with duration
of more than six months, was significantly more common in pa-
tientswithUCandCDthanhealthy controls. In addition, patients
with IBD experiencing chronic fatigue have significantly higher
levels of disease-related worries and concerns (Jelsness-Jørgensen
2012). Reduced energy level is a leading and consistent con-
cern among individuals with IBD (Drossman 1989; Casati 2000;
Casellas 2001; De Rooy 2001; Jelsness-Jørgensen 2011b). In ad-
dition, IBD-related fatigue negatively impacts on health-related
quality of life and activities of daily living (Minderhoud 2003;
Jelsness-Jørgensen 2011c; Graff 2011; Czuber-Dochan 2013a;
Czuber-Dochan 2013b; Opheim 2014). Despite the high preva-
lence of chronic fatigue in IBD, this subjective complaint remains
largely ignored in the IBD literature, particularly regarding the
investigation of underlying mechanisms and treatment strategies
for fatigue.
Fatigue has been difficult to delineate due to the subjective na-
ture of the symptom. In chronic diseases, with consideration given
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in the context of IBD, fatigue has been defined as a ‘persistent,
overwhelming sense of tiredness, weakness or exhaustion result-
ing in a decreased capacity for physical and mental work’ (Lai
2003; Dittner 2004). Although some studies have continued to
measure fatigue in IBD from a uni-dimensional perspective, for
example in terms of prevalence (Minderhoud 2003), or severity
(Opheim 2014) only, it is now generally accepted that fatigue
is a multidimensional phenomenon, characterised by diminished
perceived physical energy, mental capacity and psychological sta-
tus (Van Langenberg 2010). These physical, cognitive and affec-
tive dimensions of fatigue form the components of generic fa-
tigue measures such as the Multidimensional Fatigue Inventory.
More recent studies have assessed fatigue using multiple dimen-
sions, such as severity/intensity, frequency, duration, distress and
impact (Bager 2012). Furthermore, the characteristics of fatigue
are captured to varying degrees by the diverse range of symptom
and quality of life measures available, including both generic and
disease specific indices (Hjollund 2007). It is known that IBD-re-
lated fatigue is associated with a number of physical, psychological
and situational factors, with increased disease activity, depression,
anxiety and stress found to be consistently associated with greater
levels of fatigue (Czuber-Dochan 2013a). As a result, the non-
specific, subjective, complex nature of fatigue can often hamper
the management of this burdensome symptom. Although health-
care professionals perceive fatigue as an important and problem-
atic symptom in patients with IBD, the management of fatigue
remains poorly understood (Czuber-Dochan 2014a). Healthcare
professionals have identified the need for more information and
education to facilitate the management of fatigue in clinical prac-
tice (Czuber-Dochan 2014b). However, the effectiveness of inter-
ventions for fatigue in IBD has not been systematically reviewed.
Description of the intervention
Given themultidimensional nature of fatigue involving biological,
psychosocial, and behavioural processes (Opheim 2014), pharma-
cological andnon-pharmacological interventions either alone or in
combination may help to improve or alleviate fatigue. Pharmaco-
logical interventions involve the administration of drugs through
any route. Non-pharmacological interventions may include any
type of physical, psychological, psychosocial, behavioural or edu-
cational interventions. Interventions have been developed to ad-
dress the problem of IBD-related fatigue either directly or indi-
rectly. For example, directly in terms of an intervention specifically
aimed at improving or alleviating fatigue (Vogelaar 2014), or indi-
rectly in terms of an intervention aimed at the overall management
of IBD which assesses fatigue as an outcome (Garcia-Vega 2004).
However, there is uncertainty regarding the effectiveness of these
interventions in alleviating fatigue, particularly in the long term.
How the intervention might work
Interventions may address the physical, psychological or situa-
tional factors contributing to fatigue. It is important that these
contributory factors are clearly understood in order to target in-
terventions effectively. For example, where fatigue is related to
a physical problem such as anaemia, iron supplements or intra-
venous iron therapy may be beneficial. Alternatively, if the physi-
cal issue is inflammation due to a disease flare, a pharmacological
intervention such as biological therapy may be valuable. If altered
mood is a factor contributing to fatigue, psychosocial behavioural
interventions may be valuable. Often fatigue is influenced by a
number of factors, therefore a multi-component intervention may
be an effective approach.
Why it is important to do this review
The incidence of IBD has been increasing over time (Molodecky
2012). Fatigue has been identified as the most burdensome symp-
tom experienced by individuals with IBD that impacts negatively
on all aspects of daily life (Wilson 2012; Farrell 2013). Due to
the increasing prevalence, debilitating character and unknown
etiology, interventions for IBD-related fatigue have received in-
creased attention. Recently, in other chronic conditions which are
associated with fatigue there has been an increase in the num-
ber of Cochrane reviews on interventions for fatigue. For exam-
ple for cancer-related fatigue there are reviews assessing the effect
of pharmaceutical interventions (Minton 2010), blood transfu-
sions (Preston 2012), exercise (Cramp 2012), education (Bennett
2009), and psychosocial interventions (Goedendorp 2009). How-
ever, unlike cancer and other chronic conditions such as multi-
ple sclerosis (Heine 2015), peripheral neuropathy (White 2014)
and rheumatoid arthritis (Cramp 2013), no systematic review has
been undertaken to assess the effects of interventions for fatigue
in IBD. It is therefore proposed to systematically review and syn-
thesise existing evidence on the effects of interventions for fatigue
in individuals with IBD.
O B J E C T I V E S
The aim of this review is to assess the efficacy and safety of inter-
ventions for fatigue in IBD.
M E T H O D S
Criteria for considering studies for this review
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Types of studies
All types of randomised controlled trials (RCTs) will be considered
for inclusion.
Types of participants
Children, adolescents and adults of all ages with a clinical diag-
nosis of Crohn’s disease, ulcerative colitis (with or without a total
colectomy), or any other form of IBD (e.g. indeterminate colitis
or IBD unclassified) will be considered for inclusion. Participants
will be included regardless of whether disease status is active or in
remission.
Types of interventions
Any pharmacological and non-pharmacological interventions de-
signed to help alleviate fatigue in individuals with IBD will be
included. To be eligible for inclusion, an intervention must have
a focus on fatigue explicitly stated in its aims, content, or as a
primary or secondary outcome measure.
The following comparisons will be considered:
1. Pharmacological versus non-pharmacological;
2. Pharmacological versus pharmacological (different drugs or
same drugs with different doses and time intervals);
3. Pharmacological versus usual or standard care;
4. Non-pharmacological versus usual or standard care;
5. Non-pharmacological versus non-pharmacological
(different non-pharmacological interventions or same non-
pharmacological intervention with different formats); or
6. Any of the above versus placebo.
Interventions may be delivered in any form, for example but not
limited to, face to face, telephone, the internet, or technology in
the case of non-pharmacological interventions. Interventions may
be delivered individually or be group focused andoccur in different
settings such as a clinic or home environment.
Types of outcome measures
Primary outcomes
The primary outcome for this review will be fatigue. Therefore,
eligible studies for inclusion must have fatigue or loss of energy
measured as a primary or secondary outcome. Measures of fa-
tigue will be self-reported as it is a subjective phenomenon and
these instruments may be generic or disease specific. Examples
of generic self-reported measures include but are not limited to:
the Fatigue Severity Scale (Krupp 1989), Chalder Fatigue Scale
(Chalder 1993), Fatigue Impact Scale (Fisk 1994; Fisk 2002), Vi-
sual Analogue Scale of Fatigue (Lee 1991), Piper Fatigue Scale
(Piper 1998), Functional Assessment of Chronic Illness Therapy -
Fatigue (Yellen 1997),Multidimensional Fatigue Inventory (Smets
1996), and the Multidimensional Assessment of Fatigue (Tack
1991). An example of a disease specific measure includes the In-
flammatory Bowel Disease fatigue scale (Czuber-Dochan 2014c).
In addition, studies that report data on fatigue, loss of energy,
vigour and vitality which was assessed as a single question or as
a subscale of a questionnaire (e.g. the vitality subscale of the SF-
36 or Inflammatory Bowel Disease Questionnaire (IBDQ) (Ware
1992; Irvine 1999)) will be included. Multidimensional charac-
teristics of fatigue symptoms may be measured. For example, these
characteristics may include intensity, severity, frequency, duration,
distress or dimensions including physical fatigue, mental fatigue
or general fatigue.
Secondary outcomes
Secondary outcomes will include:
1. Any measure of quality of life (e.g. SF-36 or IBDQ); and
2. Adverse events.
Adverse events will include:
1. The proportion of participants who experience any adverse
event (i.e. an unfavourable outcome occurring during, but not
necessarily caused by the intervention);
2. Serious adverse events (i.e. an adverse event that results in
death, requires hospitalisation or a life-threatening event,
resulting in a persistent or significant disability); and
3. Withdrawal due to an adverse event.
Search methods for identification of studies
Electronic searches
We will search MEDLINE, CINAHL, EMBASE and PsycINFO
from inception to date. We will also search the Cochrane IBD
Group Specialized Register and the Cochrane Central Register of
Controlled trials (CENTRAL) for applicable RCTs. The search
strategies will be modified for each database. Search limits will
include humans and English only. The search strategies will use
the relevant database filters or the recommended Cochrane search
string for the identification of RCTs (Lefebvre 2011). The search
strategies for each database are reported in Appendix 1, Appendix
2, Appendix 3, Appendix 4, Appendix 5 and Appendix 6. One
author (DF)will liaise with theCochrane IBDGroupTrials Search
Coordinator for the identification of potentially eligible studies.
Searching other resources
To identify other relevant published, unpublished and ongoing
trials we will:
1. Examine the reference lists of included studies and review
articles for additional citations;
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2. Search ongoing trials and research registers including the
Current Controlled Trials register (www.controlled-trials.com),
ClinicalTrials.gov (www.clinicaltrials.gov) and the WHO
International Clinical Trials Registry Platform (ICTRP)
(www.who.int/ictrp/en/), using the search terms ’fatigue’ and
’inflammatory bowel disease’ or ‘ulcerative colitis’ or ‘Crohn’s
disease’;
3. Contact trial authors, known specialists in the field and
pharmaceutical companies to identify further published and
unpublished trials and ask if they are willing to disclose their
unpublished data; and
4. Search published abstracts from conference proceedings,
including the European Crohn’s and Colitis Organisation
Congress, Digestive Disease Week and Advances in
Inflammatory Bowel Diseases.
Data collection and analysis
Selection of studies
Initially, two review authors (DF, MA) will independently screen
titles and abstracts identified by the search and exclude those stud-
ies that are obviously not relevant to the review. The remaining
titles and abstracts will be independently examined for eligibility
by two review authors (DF, ES) based on the predetermined in-
clusion criteria described above. Full text papers will be retrieved
for all studies appearing to meet the inclusion criteria and will
be read independently by two review authors (DF, ES). We will
only include trials with a heterogeneous sample of disorders,if rel-
evant data from participants with IBD can be extracted. We will
contact study authors where information is unclear or missing in
order to reach a decision about inclusion. Disagreement about the
selection of a study will be resolved by consensus. In the event a
consensus cannot reached, arbitration will be sought from a third
author (CN).
Data extraction and management
For each included study, two review authors will independently
extract and document the relevant data using standardised data
extraction forms. The lead author (DF) will extract data for all
included trials. Second independent extraction of data from in-
cluded trials will be shared between three review authors (WCD
or LPJJ or MA). If necessary, study authors will be contacted to
provide additional (unpublished) relevant information. We will
resolve any disagreements by consensus including discussion with
two additional authors (ES and CN). We will gather data on the
following and document in both data extraction forms and Review
Manager 5:
Study
• Study aim
Participant characteristics
• Number of participants
• Setting of study
• Country of origin
• Demographic characteristics such as age and gender
• Disease characteristics such as disease type, disease status
and treatment type
• Inclusion and exclusion criteria for participation in the
study
Intervention characteristics
For each arm:·
• Assignment to groups·
• The aim, type, mode and content of the intervention·
• Time points of delivery ·
• Duration of the intervention, number and duration of
sessions/dose
• Providers of the intervention
• Comparison intervention/s
• Setting of the intervention
• Participant adherence
Outcomes
• Time, frequency and duration at which outcomes are
measured
• Instruments used for key primary and secondary outcomes
• Adverse events
Others
• Funding
• Declaration of interest
• Sample size and evidence of power calculation statistical
analysis.
• Follow up - withdrawal/dropout
Assessment of risk of bias in included studies
For each study, the authors who extracted the data from the in-
cluded studies will also independently assess methodological qual-
ity using the Cochrane risk of bias tool (Higgins 2011a). We
will assess trials for random sequence generation, allocation con-
cealment, blinding (participants, personnel and outcome asses-
sors), incomplete outcome data, outcome misclassification, selec-
tive outcome reporting and other potential sources of bias. We
will then make a judgment on each of these criteria relating to the
risk of bias, of ’low risk of bias’, ’high risk of bias’ or ’unclear risk
of bias’.
We will use the GRADE criteria (risk of bias, inconsistency, im-
precision, indirectness and publication bias) to assess the overall
quality of evidence for the prespecified primary and secondary
outcomes (Schünemann 2011a; Schünemann 2011b). All deci-
sions to downgrade or upgrade the quality of the evidence will be
explained using footnotes.
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If agreement cannot be achieved by the two review authors (DF
and WCD or LPJJ or MA) through discussion, another two other
review authors (ES and CN) will provide consensus assessment.
Using the GRADEpro software, we will create a ‘Summary of
findings’ table for the following outcomes:
• Fatigue;
• Quality of life; and
• Adverse events.
Measures of treatment effect
We will use the Cochrane Collaboration’s Review Manager Soft-
ware, RevMan 5, for all analyses. Outcomes will be recorded both
at the end of the intervention period and at the end of the follow-
up for the purpose of comparison between the intervention and
control groups. We will calculate the mean difference (MD) and
the corresponding 95% confidence interval (CI) for continuous
outcomes. We will calculate the risk ratio (RR) and 95%CI for di-
chotomous outcomes (e.g. fatigue or no fatigue). We will calculate
the number needed to treat for an additional beneficial outcome
(NNTB) where appropriate.
Unit of analysis issues
The level at which randomisation occurs will be accounted for in
the data analysis. We expect that participants will be individually
randomised to one of two groups, where the unit of analysis will
be the individual.
Where groups of individuals are randomised together to the same
intervention (i.e. cluster-randomised trials), the group will be the
unit of analysis. Group level interventions are often analysed and
reported at an individual rather than a group level, or without
adjusting for group effect. Authors will be contacted for further
information if these group data are not reported.
Where individuals undergo more than one intervention during
the period of the study (i.e. in a cross-over trial), an assessment of
the suitability of this method for the condition and intervention in
question and the likelihood of serious carry-over will be addressed.
If neither carry-over nor period effects are an issue, we will follow
the methods of analysis for cross-over trials as recommended in
Chapter 16 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011b).
Wewill follow the recommendations outlined inChapter 16 of the
Cochrane Handbook for Systematic Reviews of Interventions for
studies where events may reoccur, studies where there are multiple
treatment attempts, and studies where there are multiple inter-
vention groups or repeated observations on participants (Higgins
2011b).
Dealing with missing data
Where data are missing, we will contact the trial authors and re-
quest themissing data. If this information is unattainable, an avail-
able case analysis will be undertaken by analysing only the available
data (i.e. ignoring the missing data). If change scores are not avail-
able and the mean change can be calculated, standard deviations
will be imputed from baseline data using methods recommended
in Chapter 16 of the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011b). If the number of patients ran-
domised to each group and the number of drop outs are known, a
worst case intention-to-treat (ITT) analysis, whereby all drop outs
are assumed to be treatment failures, will be calculated.
Assessment of heterogeneity
The studies will be assessed for clinical homogeneity with re-
gards to participants, interventions, and outcomes. A meta-anal-
ysis would not be appropriate for studies judged to be clinically
heterogeneous. We plan to assess heterogeneity as follows.
1. We will review the results of the Chi2 test to determine if
the heterogeneity is statistically significant. A P value of 0.10 will
be considered statistically significant.
2. If the Chi2 test indicates statistically significant
heterogeneity, we will quantify the heterogeneity across studies
by reporting the I2 results. An I2 value of 25% represents low
heterogeneity, 50% represents moderate heterogeneity and 75%
represents high heterogeneity.
3. If there is significant heterogeneity, the forest plot will be
visually inspected and a sensitivity analysis performed, excluding
any obvious outliers, to assess if this explains the heterogeneity.
For example, if the original pooled analysis had an I2 value of
68% and after the outlier study (or studies) was excluded the I2
value changed to 22%. If the sensitivity analysis appears to
explain the heterogeneity, the outlier study (or studies) will be
examined to determine if it differs from the other studies in the
pooled analysis, in a way that could explain the heterogeneity.
For example, the outlier study may include participants with
both active and quiescent disease, while the other studies in the
pooled analysis enrolled patients with quiescent disease only.
4. Finally if heterogeneity is suspected, the possibility of
utilising a random-effects model of meta-analysis will be
considered as recommended in Chapter 9 of the Cochrane
Handbook for Systematic Reviews of Interventions (Deeks
2011).
Assessment of reporting biases
All studies will be assessed for reporting bias. If reporting bias is
suspected, we will attempt to contact trial authors and request
missing outcome data. For example, results for pre-specified out-
comes that were not reported in the paper. Alternatively, if this
information is unattainable and there are an appropriate number
of studies in the pooled analysis (i.e. > 10 studies), we will explore
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potential publication bias by testing for funnel plot asymmetry
(Sterne 2011).
Data synthesis
Where appropriate, the data from included studies will be com-
bined in a meta-analysis. Data will be pooled when patients, inter-
ventions and outcomes are sufficiently similar, which will be deter-
mined by consensus. We will pool statistically homogeneous stud-
ies (I2 < 50%) using a fixed-effect model. We will pool statistically
heterogeneous (I2 ≥ 50%) studies using a random-effects model.
Data will not be pooled if there is a high degree of statistical het-
erogeneity (I2 > 75%). For continuous outcomes, we will calculate
the pooled mean difference (MD) and corresponding 95% con-
fidence interval (CI). Where different scales are used to measure
the same underlying construct, we will calculate the standardised
mean difference (SMD) and corresponding 95% CI. Continuous
data will be combined only where (i) means and standard devia-
tions are available or calculable and (ii) there is no clear evidence of
a skewed distribution (Deeks 2011). For dichotomous outcomes,
we will calculate the pooled RR and corresponding 95% CI. Ac-
cording to Cohen 1977, we will classify effect sizes into small (<
0.2), medium (0.2 to 0.8) and large (> 0.8).
Subgroup analysis and investigation of heterogeneity
If sufficient power and data are available, subgroup analysis will
be performed for the following subsets: disease type (Crohn’s dis-
ease, ulcerative colitis); disease activity (active disease, inactive dis-
ease), sex (male, female); age groups (child, adolescents, adults,
elderly), co-morbidities, and intervention type (pharmacological
non-pharmacological). All review authors will be involved in in-
terpreting the analyses. We will restrict subgroup analyses to look-
ing at effects of subgroups on the primary outcome.
Sensitivity analysis
Sensitivity analysis will be performed, where appropriate, to ex-
plore the effects of risk of bias. Studies identified as high risk of
bias will be excluded from the pooled analysis to see if the effect
estimate changes in a substantive way. If no substantive difference
exists, the studies with a high risk of bias will be included in the
main analysis. For allocation concealment, we intend to re-analyse
the data including only those trials with adequate concealment of
allocation. Finally for blinding of outcome assessment, trials with
double blinding of outcome assessment will be included in a re-
analysis, due to the subjective nature of fatigue. Sensitivity analy-
sis will be conducted for the primary outcome only. We will also
compare the results of any ’available case’ analysis with a worst
case ITT analysis to see if the effect estimate changes.
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A P P E N D I C E S
Appendix 1. EMBASE search strategy
1. exp Crohn disease/ or crohn*.mp.
2. (colitis and ulcerat*).mp. or exp ulcerative colitis/
3. (inflammatory bowel disease* or IBD).mp.
4. 1 or 2 or 3
5. random$.mp.
6. factorial$.mp.
7. (crossover$ or cross over$ or cross-over$).mp.
8. placebo$.mp.
9. single blind.mp.
10. double blind.mp.
11. triple blind.mp.
12. (singl$ adj blind$).mp.
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13. (double$ adj blind$).mp.
14. (tripl$ adj blind$).mp.
15. assign$.mp.
16. allocat$.mp.
17. crossover procedure/
18. double blind procedure/
19. single blind procedure/
20. triple blind procedure/
21. randomized controlled trial/
22. or/1-17
23. (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.)
24. 18 not 19
25. exp fatigue/
26. exp chronic fatigue syndrome/
27. (physical fatigue OR mental fatigue OR muscle fatigue).mp.
28. (energy OR tired* OR sleep* OR drows* OR letharg* OR lassitude OR weari* ).mp.
29. (exhaust* OR listless* OR apath* OR malaise).mp.
30. ((asthenia OR asthenic) adj3 syndrome).tw.
31. ((lack OR loss OR lost) adj3 (energy OR vigo* OR vitality).tw.
32. 25 or 26 or 27 or 28 or 29 or 30 or 31
33. 4 AND 24 AND 32
Appendix 2. MEDLINE search strategy
1. exp Crohn disease/ or crohn*.mp.
2. (colitis and ulcerat*).mp. or exp ulcerative colitis/
3. (inflammatory bowel disease* or IBD).mp.
4. 1 or 2 or 3
5. random$.mp.
6. factorial$.mp.
7. (crossover$ or cross over$ or cross-over$).mp.
8. placebo$.mp.
9. single blind.mp.
10. double blind.mp.
11. triple blind.mp.
12. (singl$ adj blind$).mp.
13. (double$ adj blind$).mp.
14. (tripl$ adj blind$).mp.
15. assign$.mp.
16. allocat$.mp.
17. crossover procedure/
18. double blind procedure/
19. single blind procedure/
20. triple blind procedure/
21. randomized controlled trial/
22. or/5-17
23. (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.)
24. 18 not 19
25. exp fatigue/
26. exp chronic fatigue syndrome/
27. (physical fatigue OR mental fatigue OR muscle fatigue).mp.
28. (energy OR tired* OR sleep* OR drows* OR letharg* OR lassitude OR weari* ).mp.
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29. (exhaust* OR listless* OR apath* OR malaise).mp.
30. ((asthenia OR asthenic) adj3 syndrome).tw.
31. ((lack OR loss OR lost) adj3 (energy OR vigo* OR vitality).tw.
32. 25 or 26 or 27 or 28 or 29 or 30 or 31
33. 4 AND 24 AND 32
Appendix 3. Cochrane Library search strategy
#1 MeSH descriptor: [Inflammatory Bowel Diseases] explode all trees
#2 crohn*
#3 ulcerative colitis
#4 colitis
#5 proctitis
#6 ileitis
#7 #1 or #2 or #3 or #4 or #5 or #6
#8 MeSH descriptor: [Fatigue] explode all trees
#9 “chronic fatigue” or “physical fatigue” or “mental fatigue” or “muscle fatigue”
#10 energy or tired* or sleep* or drows* or letharg* or lassitude or weari* or exhaust* or listless* or apath* or malaise
#11 #8 or #9 or #10
#12 #7 and #11
Appendix 4. CINAHL search strategy
1. (TI fatigue or AB fatigue) OR (TI energy or AB energy) OR (TI sleep* or AB sleep*)OR (TI drows* or AB drows*) OR (TI lethargy*
or AB lethargy*) OR (TI lassitude or AB lassitude) OR (TI weari* or AB weari*) OR (TI exhaust* or AB exhaust*) OR (TI listless* or
AB listless*) OR (TI apath* or AB apath*) OR (TI malaise or AB malaise)
2. (TI inflammatory bowel or AB inflammatory bowel) OR (TI IBD or AB IBD) OR (TI Crohn* or AB Crohn*) OR (TI CD* or AB
CD*) OR (TI colitis* or AB colitis*) OR (TI UC or AB UC) OR (TI proctitis or AB proctitis) OR (TI ileitis or AB ileitis)
Appendix 5. PsycINFO search strategy
1. TI(fatigue OR energy OR sleep* OR drows* OR lethargy* OR lassitude OR weari* OR exhaust* OR listless* OR apath* OR
malaise) AND TI(inflammatory bowel OR IBS OR Crohn* OR CD OR colitis OR UC OR proctitis OR ileitis)
Appendix 6. clinicaltrials.gov search strategy
(fatigue OR energy OR sleep* OR drows* OR lethargy* OR lassitude OR weari* OR exhaust* OR listless* OR apath* OR malaise) |
(inflammatory bowel OR IBS OR Crohn* OR CD OR colitis OR UC OR proctitis OR ileitis)
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